Abstract Objective To investigate the effect of chemotherapy combined with biological immunotherapy on clinical efficacy and survival of advanced prostate cancer.Methods Ninety-six patients with advanced prostate cancer who were treated from September 2013 to March 2016 in our hospital were randomly divided into two groups. The control group was given chemotherapy alone, the observation group was given chemotherapy combined with biological immunity for treatment. The clinical efficacy and immunohistochemical response of patients with advanced prostate cancer were compared and analyzed. After 4 months of treatment, the patients were followed up for 1 year. The mortality, survival and time to disease progression (TTP) as well as the occurrence of adverse reactions of the two groups were observed.Results After treatment, the total effective rate of the observation group was 87.5% (42/48), which was significantly higher than that of the control group [68.8%(33/48]. There was significant difference between the two groups (P<0.05). The numbers of Tlymphocytes, T helper cells,Tsuppressor cells, natural killer cells and naturak killer T were significantly higher than that in the control group in the external T lymph. There was a significant difference between the two groups (P<0.05). After 1 year of follow-up, the mortality rate of the observation group was lower than that of the control group, and the survival time (36.6 ± 5.4) months was higher than that of the control group (20.7 ± 7.2) months, TTP of the observation group was higher than that of the control group [(29.8 ± 5.7) months vs.（19.7±9.3）months] (P<0.05). The adverse reaction rate (22.9%) in the observation group was significantly lower than that in the observation group (43.8%), and the difference between the two groups was statistically significant (P<0.05) .Conclusions Chemotherapy combined with biological immunotherapy is effective in advanced prostate cancer, which can effectively enhance the activity of immune function cells, prolong survival time, TTP, reduce mortality, reduce the incidence of adverse reactions and improve the quality of life after treatment.
